Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 907-913

  Ambrusko, Steven J ^a   Gunawardena, Sriya ^a   Sakara, Allison ^a   Windsor, Beth ^a   Lanford, Lizabeth ^a   Michelson, Peter ^a   Krishnamurti, Lakshmanan ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Children; Pulmonary hypertension; Sickle cell hemoglobinopathy

Indexed keywords

HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; ASTHMA; BLOOD VESSEL OCCLUSION; CEREBROVASCULAR DISEASE; CHILD; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTPATIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; REVIEW; SICKLE CELL ANEMIA; SLEEP APNEA SYNDROME; STEADY STATE; TRICUSPID REGURGITANT JET VELOCITY; TRICUSPID VALVE REGURGITATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; MALE; PULMONARY ARTERY; RETROSPECTIVE STUDIES; TRICUSPID VALVE INSUFFICIENCY;

EID: 33749998954     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20791     Document Type: Review

References (42)

1. Lin EE, Rodgers GP, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep 2005;4:117-125.
2. Buchanan GR, Debaun MR, Quinn CT, et al. Sickle cell disease. Hematology. Am Soc Hematol Educ Program Book 2004; 35-47.
3. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med 2004;350:857-859.
4. Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004;117:665-669.
5. Boussaada R, Boubaker K, Mourali S, et al. [Pulmonary hypertension in sickle cell anemia. A case report]. Tunis Med 2004;82:180-184.
6. Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:2521-2522; author reply 2521-2522.
7. Hassoun PM, Krishnan JA. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:2521-2522; author reply 2521-2522.
8. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
9. Ahmed S, Siddiqui AK, Sadiq A, et al. Echocardiographic abnormalities in sickle cell disease. Am J Hematol 2004;76:195-198.
10. Siddiqui AK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgrad Med J 2003;79:384-390.
11. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood 2003;101:1257-1261.
12. Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med 2003;168:3-4.
13. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: An autopsy study. Br J Haematol 2003;123:359-365.
14. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: A clinicopathologic study of 20 cases. Hum Pathol 2002;33:1037-1043.
15. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol 2001;38:333-342.
16. Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999;27:2563-2568.
17. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999;26:74-84.
18. Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994;74:626-628.
19. Verresen D, De Backer W, Vermeire P. Pulmonary hypertension and sickle hemoglobinopathy. Chest 1990;98:1042.
20. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 1982;73:814-821.
21. Du ZD, Roguin N, Milgram E, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532-537.
22. Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 1991;4:629-631.
23. Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004; 34:442-453.
24. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005;294:81-90.
25. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group. N Engl J Med 2000;342:1855-1865.
26. Jais X, Till SJ, Cynober T, et al. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: Gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin 2003;27:139-147.
27. Cowick DLeon W. Therapeutic splenectomy. Am Surg 1975;41:567-570.
28. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005;293:1653-1662.
29. Yamakawa H, Shiomi T, Sasanabe R, et al. Pulmonary hypertension in patients with severe obstructive sleep apnea. Psychiatry Clin Neurosci 2002;56:311-312.
30. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005;294:81-90.
31. Manci EA. Clinicopathological correlations in chronic sickle cell lung disease. Abstract # 1667. Blood 2004;104:463a.
32. Eysmann SB, Palevsky HI, Reichek N, et al. Two-dimensional and doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989;80:353-360.
33. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386.
34. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary pulmonary hypertension study group. Circulation 1997;95:1479-1486.
35. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219.
36. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389.
37. Nolan VG, Wyszynski DF, Farrer LA, et al. Hemolysis-associated priapism in sickle cell disease. Blood 2005;106:3264-3267.
38. Gladwin MT. Unraveling the hemolytic subphenotype of sickle cell disease. Blood 2005;106:2925-2926.
39. Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 1999;44:274-282.
40. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
41. Rosival V. The role of pulmonary hypertension in the pathogenesis of bronchial asthma. Med Hypotheses 1990;33:7-9.
42. Rothman A, Kulik TJ. Pulmonary hypertension and asthma in two patients with congenital heart disease. Am J Dis Child 1989;143:977-979.